A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma

M. H. Langenberg; L. Gluck; V. Weger; R. Frank; F. Eskens; J. Y. Blay; J. C. Soria; S. Chawla; M. Gounder; A. Wagner; Y. Zhang; P. Kambuj; R. Loberg; H. Henary

doi:10.1016/S0959-8049(16)32682-X

A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma

M. H. Langenberg
, L. Gluck
, V. Weger
, R. Frank
, F. Eskens
, J. Y. Blay
, J. C. Soria
, S. Chawla
, M. Gounder
, A. Wagner
, Y. Zhang
, P. Kambuj
, R. Loberg
, H. Henary

Research output: Contribution to journal › Meeting Abstract › Other research output

Original language	English
Pages (from-to)	S34-S34
Journal	European Journal of Cancer
Volume	69
Issue number	Suppl. 1
DOIs	https://doi.org/10.1016/S0959-8049(16)32682-X
Publication status	Published - Dec 2016

Access to Document

10.1016/S0959-8049(16)32682-X

Cite this

Langenberg, M. H., Gluck, L., Weger, V., Frank, R., Eskens, F., Blay, J. Y., Soria, J. C., Chawla, S., Gounder, M., Wagner, A., Zhang, Y., Kambuj, P., Loberg, R., & Henary, H. (2016). A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma. European Journal of Cancer, 69(Suppl. 1), S34-S34. https://doi.org/10.1016/S0959-8049(16)32682-X

@article{f8fd864acfa44680aaafe99cf1396570,

title = "A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma",

author = "Langenberg, \{M. H.\} and L. Gluck and V. Weger and R. Frank and F. Eskens and Blay, \{J. Y.\} and Soria, \{J. C.\} and S. Chawla and M. Gounder and A. Wagner and Y. Zhang and P. Kambuj and R. Loberg and H. Henary",

note = "28 EORTC – NCI – AACR Symposium on Molecular Targets and Cancer Therapeutics 29 November 2016 - 02 December 2016",

year = "2016",

month = dec,

doi = "10.1016/S0959-8049(16)32682-X",

language = "English",

volume = "69",

pages = "S34--S34",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

number = "Suppl. 1",

}

Langenberg, MH, Gluck, L, Weger, V, Frank, R, Eskens, F, Blay, JY, Soria, JC, Chawla, S, Gounder, M, Wagner, A, Zhang, Y, Kambuj, P, Loberg, R & Henary, H 2016, 'A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma', European Journal of Cancer, vol. 69, no. Suppl. 1, pp. S34-S34. https://doi.org/10.1016/S0959-8049(16)32682-X

TY - JOUR

T1 - A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma

AU - Langenberg, M. H.

AU - Gluck, L.

AU - Weger, V.

AU - Frank, R.

AU - Eskens, F.

AU - Blay, J. Y.

AU - Soria, J. C.

AU - Chawla, S.

AU - Gounder, M.

AU - Wagner, A.

AU - Zhang, Y.

AU - Kambuj, P.

AU - Loberg, R.

AU - Henary, H.

N1 - 28 EORTC – NCI – AACR Symposium on Molecular Targets and Cancer Therapeutics 29 November 2016 - 02 December 2016

PY - 2016/12

Y1 - 2016/12

U2 - 10.1016/S0959-8049(16)32682-X

DO - 10.1016/S0959-8049(16)32682-X

M3 - Meeting Abstract

SN - 0959-8049

VL - 69

SP - S34-S34

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - Suppl. 1

ER -